2026-07-21T09:09:10Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/180462024-11-28T15:03:25Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16978
Repisalud author Salvador-Martín, Sara author Raposo-Gutiérrez, Irene author Navas-López, Víctor Manuel author Gallego-Fernández, Carmen author Moreno-Álvarez, Ana author Solar-Boga, Alfonso author Muñoz-Codoceo, Rosana author Magallares, Lorena author Martínez-Ojinaga, Eva author Fobelo, María J. author Millán-Jiménez, Antonio author Rodriguez-Martinez, Alejandro author Vayo, Concepción A. author Sánchez, Cesar author Tolin, Mar author Bossacoma, Ferrán author Pujol-Muncunill, Gemma author González de Caldas, Rafael author Loverdos, Inés author Blanca-García, José A. author Segarra, Oscar author Eizaguirre, Francisco J. author García-Romero, Ruth author Merino-Bohórquez, Vicente author Sanjurjo-Sáez, María author López-Fernández, Luis A. authoraffiliation [Salvador-Martín,S; Raposo-Gutiérrez,I; Sanjurjo-Sáez,M; López-Fernández,LA] Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. [Navas-López,V] Pediatric Gastroenterology and Nutrition Unit, Hospital Regional Universitario de Málaga, IBIMA Multidisciplinary Group for Pediatric Research, Málaga, Spain. [Gallego-Fernández,C] Pharmacy Department, Hospital Regional Universitario de Málaga, Málaga, Spain. [Moreno-Álvarez,A; Solar-Boga,A] Pediatric Gastroenterology Unit, Department of Pediatrics, A Coruña University Hospital, A Coruña, Spain. [Muñoz-Codoceo,R] Department of Pediatric Gastroenterology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Magallares,L; Martínez-Ojinaga,E] Department of Pediatric Gastroenterology, University Hospital La Paz, Madrid, Spain. [Fobelo,MJ] Pharmacy Service, Hospital Virgen de Valme, Sevilla, Spain. [Millán-Jiménez,A] Pediatric Gastroenterology Unit, Hospital Virgen de Valme, Sevilla, Spain. [Rodriguez-Martinez,A] Pediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital Universitario Virgen del Rocio, Seville, Spain. [Vayo,CA] Pharmacy Service, Hospital Universitario Virgen del Rocio, Seville, Spain. [Sánchez,C; Tolin,M] Gastroenterology Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. [Bossacoma,F] Fundació Sant Joan de Déu, Fundació Salut Emporda, Barcelona, Spain. [Pujol-Muncunill;G] Department of Pediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain. [González de Caldas,R] Pediatric Gastroenterology Unit, Hospital Reina Sofía, Córdoba, Spain. [Loverdos,I] Pediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital de Sabadell, Corporació Sanitària Universitària Parc Taulí, Barcelona, Spain. [Blanca-García,JA] Pediatric Gastroenterology Unit, Hospital Puerta del Mar, Cadiz, Spain. [Segarra,O] Pediatric Gastroenterology Unit, Hospital Universitario Vall d’Hebrón, Barcelona, Spain. [Eizaguirre,FJ] Pediatric Gastroenterology Unit, Hospital Universitario Donostia, San Sebastián, Spain. [García-Romero,R] Pediatric Gastroenterology Unit, Hospital Infantil Miguel Servet, Zaragoza, Spain. [Merino-Bohórquez,V] UGC Pharmacy Department, Hospital Virgen de la Macarena, Sevilla, Spain. 2024-02-12T19:46:10Z 2024-02-12T19:46:10Z 2020-05-09 10.3390/ijms21093364 1422-0067 International Journal of Molecular Sciences http://hdl.handle.net/10668/3700 32397546 http://hdl.handle.net/20.500.12105/18046 Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2-∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies. eng Biomarker Gene expression Infliximab Adalimumab Ulcerative colitis Crohn’s disease Biomarcadores Expresión génica Colitis ulcerosa Enfermedad de Crohn Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease research article